The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms.

Jianfei ZengWeizhi ZhangXiaobing LuHui ZhouJing HuangZhenyu XuHairong LiaoJiaquan LiangMeihong LiangChan YeTing SunYutong HuQi SheHaixia ChenQian GuoLiuJiao YanRenrong WuDonghong Cui

Published in: European archives of psychiatry and clinical neuroscience (2023)

Our study suggests that SFN may potentially serve as a safe adjunctive intervention to improve the negative symptoms of schizophrenia. The potential mechanism by which SFN improves negative symptoms in schizophrenia patients may involve its anti-inflammatory properties, specifically its ability to reduce HsCRP levels. Trial registration ClinicalTrial.gov (ID: NCT03451734).

Keyphrases

bipolar disorder
end stage renal disease
anti inflammatory
ejection fraction
randomized controlled trial
newly diagnosed
chronic kidney disease
clinical trial
prognostic factors
peritoneal dialysis
study protocol
patient reported outcomes
phase iii
risk assessment
patient reported
open label
double blind